| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $2,942,337 | 11 | 100 |
| Singh Sanjay R | EVP Technical Operations | 0 | $0 | 1 | $94,448 | $-94,448 |
| Tross Stuart A | Chief People & Workpl Officer | 0 | $0 | 1 | $250,980 | $-250,980 |
| Castagna Michael | Chief Executive Officer | 0 | $0 | 1 | $601,114 | $-601,114 |
| Binder Steven B. | director | 0 | $0 | 4 | $982,305 | $-982,305 |
| Thomson David | EVP Genl Counsel & Secretary | 0 | $0 | 4 | $1.01M | $-1.01M |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Over the last 12 months, insiders at MannKind Corporation have bought $0 and sold $2.94M worth of MannKind Corporation stock.
On average, over the past 5 years, insiders at MannKind Corporation have bought $457,437 and sold $1.84M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,147 shares for transaction amount of $9,221 was made by Castagna Michael (Chief Executive Officer) on 2022‑07‑31.
| 2025-12-02 | Sale | Castagna Michael | Chief Executive Officer | 107,920 0.035% | $5.57 | $601,114 | +2.51% | |
| 2025-12-02 | Sale | Thomson David | EVP Genl Counsel & Secretary | 147,780 0.048% | $5.57 | $823,135 | +2.51% | |
| 2025-11-14 | Sale | Singh Sanjay R | EVP Technical Operations | 18,777 0.0061% | $5.03 | $94,448 | +3.39% | |
| 2025-09-16 | Sale | Tross Stuart A | Chief People & Workpl Officer | 47,000 0.0152% | $5.34 | $250,980 | +0.37% | |
| 2025-07-16 | Sale | Thomson David | EVP Genl Counsel & Secretary | 7,466 0.0024% | $3.94 | $29,416 | +34.09% | |
| 2025-07-16 | Sale | Binder Steven B. | director | 75,367 0.0247% | $3.94 | $296,946 | +34.09% | |
| 2025-06-10 | Sale | Binder Steven B. | director | 64,085 0.0215% | $4.00 | $256,340 | +29.08% | |
| 2025-05-20 | Sale | Binder Steven B. | director | 12,078 0.004% | $4.40 | $53,143 | +3.67% | |
| 2025-05-20 | Sale | Thomson David | EVP Genl Counsel & Secretary | 2,345 0.0008% | $4.41 | $10,341 | +3.67% | |
| 2025-05-13 | Sale | Binder Steven B. | director | 80,144 0.0262% | $4.69 | $375,875 | -4.56% | |
| 2025-05-13 | Sale | Thomson David | EVP Genl Counsel & Secretary | 32,179 0.0105% | $4.68 | $150,598 | -4.56% | |
| 2024-11-22 | Sale | Binder Steven B. | director | 67,536 0.0247% | $6.89 | $465,323 | -24.71% | |
| 2024-11-15 | Sale | Binder Steven B. | director | 67,539 0.0234% | $6.76 | $456,564 | -23.38% | |
| 2024-11-06 | Sale | Tross Stuart A | Chief People & Workpl Officer | 55,000 0.0199% | $7.34 | $403,700 | -29.77% | |
| 2024-09-03 | Sale | Tross Stuart A | Chief People & Workpl Officer | 25,000 0.0094% | $6.26 | $156,500 | -13.57% | |
| 2024-08-30 | Sale | Tross Stuart A | Chief People & Workpl Officer | 80,000 0.0294% | $6.33 | $506,050 | -16.13% | |
| 2024-08-29 | Sale | Castagna Michael | Chief Executive Officer | 85,106 0.0308% | $6.30 | $536,168 | -16.98% | |
| 2024-08-29 | Sale | Binder Steven B. | EVP Special Projects | 5,055 0.0017% | $5.94 | $30,027 | -16.98% | |
| 2024-08-29 | Sale | Thomson David | EVP Genl Counsel & Secretary | 5,553 0.0019% | $5.94 | $32,985 | -16.98% | |
| 2024-07-16 | Sale | Binder Steven B. | EVP Special Projects | 2,836 0.0012% | $5.93 | $16,817 | -6.42% |
| Castagna Michael | Chief Executive Officer | 2504792 0.8159% | $14.3M | 20 | 17 | +9.73% |
| Tross Stuart A | Chief People & Workpl Officer | 1032013 0.3362% | $5.89M | 12 | 4 | +16.5% |
| Thomson David | EVP Genl Counsel & Secretary | 841719 0.2742% | $4.81M | 0 | 69 | |
| Binder Steven B. | director | 830508 0.2705% | $4.74M | 9 | 11 | +22.69% |
| Singh Sanjay R | EVP Technical Operations | 455211 0.1483% | $2.6M | 0 | 1 | |
| MANN ALFRED E | Chairman & CEO | 74750000 24.348% | $426.82M | 15 | 0 | <0.0001% |
| Edstrom Hakan | President & CEO | 1060302 0.3454% | $6.05M | 10 | 15 | +11.92% |
| Galindo Alejandro | EVP Endocrine Business Unit | 777090 0.2531% | $4.44M | 6 | 1 | +14.87% |
| HOOPER ANTHONY C | director | 338394 0.1102% | $1.93M | 1 | 0 | +48.09% |
| MUNDKUR CHRISTINE | director | 254493 0.0829% | $1.45M | 1 | 0 | +48.09% |
| Grancio Jennifer | director | 244815 0.0797% | $1.4M | 1 | 0 | +48.09% |
| KRESA KENT | director | 237589 0.0774% | $1.36M | 3 | 0 | <0.0001% |
| Richardson Peter C | Chief Scientific Officer | 122497 0.0399% | $699,457.87 | 0 | 2 | |
| McCauley Patrick | Chief Commercial Officer | 100433 0.0327% | $573,472.43 | 5 | 0 | +1.23% |
| Martens Juergen | Corporate VP and COO | 88776 0.0289% | $506,910.96 | 5 | 26 | +0.94% |
| PFEFFER MATTHEW J | director | 82617 0.0269% | $471,743.07 | 10 | 7 | +7.06% |
| COHEN ABRAHAM E | director | 56424 0.0184% | $322,181.04 | 0 | 1 | |
| ANDERSON RICHARD L | VP & CFO | 48440 0.0158% | $276,592.40 | 2 | 1 | +19.19% |
| Kendall David M | Chief Medical Officer | 41059 0.0134% | $234,446.89 | 5 | 0 | +28.17% |
| Ingram Elizabeth Garrett | Chief Marketing Officer | 31141 0.0101% | $177,815.11 | 1 | 0 | +3.17% |
| Alinaya Rosabel Realica | SVP, Investor Relations | 30091 0.0098% | $171,819.61 | 2 | 1 | +12.28% |
| Barton Courtney | Chief Compl & Privacy Officer | 29584 0.0096% | $168,924.64 | 3 | 0 | +6.05% |
| Palumbo Diane | Vice President, Human Resource | 29105 0.0095% | $166,189.55 | 3 | 27 | <0.0001% |
| Urbanski Raymond W. | Corp VP, CMO | 2924 0.001% | $16,696.04 | 0 | 1 | |
| Cheatham W Wendell | VP, Chief Medical Officer | 538 0.0002% | $3,071.98 | 2 | 4 | +0.78% |
MannKind Corporation (MNKD) | $831,902,292 | 108 | 9.34% | $1.75B |
$21,345,882 | 83 | 94.45% | $1.65B | |
$54,590,806 | 65 | 21.84% | $2.16B | |
$1,101,324,300 | 58 | 37.37% | $1.42B | |
$1,376,668 | 53 | 18.46% | $1.86B | |
$678,065,999 | 37 | -13.32% | $1.73B | |
$530,111,731 | 35 | 8.69% | $1.34B | |
$1,295,059 | 29 | 102.78% | $1.97B | |
$7,033,101 | 22 | -12.19% | $1.84B | |
$1,272,896 | 16 | 24.56% | $2.02B | |
$154,554,190 | 14 | 29.60% | $1.6B | |
$50,317,062 | 13 | -3.69% | $1.99B | |
$2,859,892 | 10 | 29.21% | $1.71B | |
$133,369,382 | 10 | 5.02% | $1.9B | |
$94,976,497 | 10 | -10.72% | $1.77B | |
$3,200,000 | 5 | -11.36% | $1.39B | |
$18,704,399 | 5 | -20.93% | $1.38B | |
$1,148,916 | 3 | -35.10% | $1.6B | |
$103,599,972 | 2 | -36.81% | $1.97B |
| Increased Positions | 108 | +36.86% | 32M | +18.34% |
| Decreased Positions | 123 | -41.98% | 29M | -16.82% |
| New Positions | 47 | New | 18M | New |
| Sold Out Positions | 45 | Sold Out | 7M | Sold Out |
| Total Postitions | 278 | -5.12% | 175M | +1.52% |
| Blackrock, Inc. | $153,599.00 | 9.35% | 28.71M | -389,822 | -1.34% | 2025-09-30 |
| Vanguard Group Inc | $94,324.00 | 5.74% | 17.63M | -530,280 | -2.92% | 2025-09-30 |
| Rubric Capital Management Lp | $61,068.00 | 3.72% | 11.41M | +11M | New | 2025-09-30 |
| State Street Corp | $57,460.00 | 3.5% | 10.74M | -5,718 | -0.05% | 2025-09-30 |
| Geode Capital Management, Llc | $39,512.00 | 2.41% | 7.39M | -232,070 | -3.05% | 2025-09-30 |
| Nitorum Capital, L.P. | $35,104.00 | 2.14% | 6.56M | -450,050 | -6.42% | 2025-09-30 |
| Ubs Group Ag | $27,792.00 | 1.69% | 5.19M | +3M | +146.67% | 2025-09-30 |
| Avoro Capital Advisors Llc | $23,908.00 | 1.46% | 4.47M | -1M | -23.61% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $21,489.00 | 1.31% | 4.02M | -37,338 | -0.92% | 2025-09-30 |
| Morgan Stanley | $20,600.00 | 1.25% | 3.85M | +1M | +39.6% | 2025-09-30 |